- About COS
- COS Membership
- Canadian Journal
- Advocacy & news
- Vision health
MD Financial Management Inc., in collaboration with Scotiabank and the Canadian Medical Association, is proud to announce a $625,000 contribution to target the pressing issue of professional burnout among Canadian physicians.
The Canadian Institute for Health Information (CIHI) has released updated data on wait times for priority procedures in Canada.
Across Canada, there has been a growing demand for and use of MIGS. However, the direct and indirect costs of MIGS can be considerable, and coverage under the public health insurance plans is inconsistent across jurisdictions.
These recommendations were developed by the Health Technology Expert Review Panel (HTERP) based on evidence reviewed in a CADTH Health Technology Assessment (HTA) report.
Through discussion with the Eye Physicians and Surgeons Association of Alberta, COS has become aware of proposed changes to Alberta regulation surrounding the disinfection of ophthalmic diagnostic instrumentation that comes into contact with the ocular surface.
Following the letter that the Canadian Ophthalmological Society sent you on March 26, 2018 regarding the impact Novartis/Alcon’s decision to discontinue Isopto Atropine 1% (Atropine) will have on Canadian ophthalmologists, the COS has been discussing the impact this discontinuation will have on other Canadian medical specialties, specifically the Canadian Psychiatric Association and the Canadian Society of Palliative Care Physicians. Our joint response to the discontinuation follows.
A new survey, commissioned by the Canadian Ophthalmological Society, revealed that most Canadians (59%) experience symptoms of potential eye disease, yet only half of these people reported they had seen a health care professional.
We have received confirmation from INNOVA Medical Ophthalmics and Dioptic Pharmaceuticals that DioFluor strips are now available and the company has started shipping them as of April 17, 2018.
In response to Novartis/Alcon’s decision to discontinue Isopto Atropine 1%, the Canadian Ophthalmological Society (COS) has discussed the impact this discontinuation will have with representatives from the following sub-specialty societies: the Canadian Association of Pediatric Ophthalmology and Strabismus (CAPOS), the Canadian Glaucoma Society (CGS), the Canadian Retina Society (CRS), and the Canadian Uveitis Society. Our joint response to the discontinuation follows.
Novartis/Alcon has announced that it is discontinuing Isopto Atropine 1%. Currently, Isopto Atropine 1% is listed as an “actual shortage” on the Drug Shortages Canada database, and Health Canada was unaware of the discontinuation when we reached out to them. Consequently, this announcement has caused some confusion regarding the actual status of Isopto Atropine 1%.
Conrad Black: How the Canadian health system saved my left eye
Conrad Black, National Post, April 13, 2013
A Black eye for health care? (commentary on Conrad Black: How the Canadian…)
Lysiane Gagnon, The Globe and Mail, April 25, 2013
Vision Loss in Canada 2011
Facts & numbers from the National Coalition for Vision Health
Going Blind and Going Forward
Outreach toolkit for use with the film ‘Going Blind’
National Physician Survey
2014 results now available
Canadian Vision Care by the Numbers:
$15.8 billion: Cost of vision loss in Canada annually
$8.6 billion: Direct health care costs annually
$7.2 billion: Indirect costs (lost earnings, care & rehabilitation, special equipment, etc.)
$30.3 billion: Annual cost of vision loss in Canada by 2032
[Source: Vision Loss in Canada 2011]